Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- Doctors at Ryukaikon Council Request Mandatory Inclusion of Expiry Dates in Product Barcodes
July 8, 2014
- MHLW OKs IFN-Free Hepatitis C Treatments
July 8, 2014
- Keiya Iida of METI to Be First “Councilor for the Promotion of Pharmaceutical and Related Industries”: MHLW
July 8, 2014
- Kiyohito Nakai to Be Appointed Pharmaceutical Management Director
July 8, 2014
- Ryukaikon Council Member Requests Rewards instead of Penalties for Early Delivery Price Settlements
July 7, 2014
- Initiatives for Drug Distribution Improvement Advanced in FY2013: Ryukaikon Council
July 7, 2014
- Yuji Kanda to Head PFSB, Kazuo Futagawa to Head HPB Following Reshuffling of MHLW Top Officials
July 7, 2014
- MHLW to Issue Business Practice Improvement Order to Novartis for Violation of ADR Reporting Requirement
July 4, 2014
- MHLW to Require RMP Submissions around August for Generics of Blue Letter-Issued Original Drugs
July 2, 2014
- Ex-Novartis Employee, Japan Unit Indicted over Diovan Data Manipulation
July 1, 2014
- Govt Tax Panel Proposes Maintenance of Scaled-Down R&D Tax Credits
June 30, 2014
- JPMA Official Calls for Partial Introduction of CDISC-Based Electronic Applications; Runup Period too Short
June 30, 2014
- Benefits of Electronic Applications to Be Shared by Patients, Companies, and Regulatory Authorities: MHLW Exec
June 30, 2014
- PAFSC’s Second Committee Supports Approval of IFN-Free Hepatitis C Treatments
June 30, 2014
- Chuikyo to Resume Discussions on Diovan Ads’ Impact on Healthcare Finances
June 27, 2014
- MHLW to Conduct Hearings over CASE-J Study, Take “Appropriate Action” against Takeda: Minister
June 27, 2014
- Drugs under Simultaneous Global Development May also Be Eligible for New Fast-Track Review System: MHLW Exec
June 26, 2014
- Govt Approves Economic Strategies, Chuikyo Likely to Discuss NHI Price Revision Frequency
June 25, 2014
- Ryukaikon to Meet on July 2; FY2013 Price Settlement Rates to Be Reported
June 25, 2014
- MHLW Issues Notification on Electronic Applications
June 24, 2014
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…